With biotech stocks stealing most of the headlines this year, it may be that PCGH has been overlooked, slipping to a 7.6% discount to NAV from parity in May. The fund has quietly plugged away, growing the dividend and continuing to benefit from the rerating of large cap pharmaceutical stocks, with volatility below the benchmark and peer group. We believe the defined exit date in the form of a liquidation resolution, due in just over three years (January 2018), should put a floor on the discou ....